320. Early Biologic Treatment May Prevent Relapses Or New Organ Involvement In Behcet's Patients With High-risk

Background/ Objectives: Conventional immunosuppressives (cIS) are the choice of treatment for major organ (ocular, vascular, central nervous (CNS) and gastrointestinal (GIS) involvement to prevent relapses and organ damage in patients with Behcet’s disease (BD). We aimed to investigate the rate of new major organ involvement in BD patients under cIS treatments during follow-up and to assess the characteristics and treatment protocols of these patients. Methods: The files of 1114 patients diagnosed with BD and followed (1992-2019) in the Marmara University Behcet’s Clinic were overviewed retrospectively. Patients with follow-up duration less than 6 months were excluded. A total of 806 patients, of whom 56% were male were included in the analysis. Demographic and clinical characteristics, follow-up and treatment data of the patients were recorded from files. Relapse of the same organ and/or new major organ development during the follow-up period of patients receiving cIS was defined as “event under cIS”. Results: Median age at diagnosis was 29 (10-65) years and median follow-up duration was 68 months (6-272). Genital ulcer, erythema nodosum and arthritis/arthralgia were more common in women, whereas papulopustular lesions, vascular and ocular involvement were more common in men (p